Journal: Advanced Science
Article Title: IR783‐Stabilized Nanodrugs Enhance Anticancer Immune Response by Synergizing Oxidation Therapy and Epigenetic Modulation
doi: 10.1002/advs.202415684
Figure Lengend Snippet: Preparation and characterization of IR/Lap/CUDC NPs. A) Size distribution and transmission electron microscopy (TEM) image of IR/Lap/CUDC NPs (Scale bar: 200 nm). B) Zeta potential of IR/Lap/CUDC NPs. C) UV–vis absorption spectra of free β ‐lap, CUDC101, IR783, and IR/Lap/CUDC NPs. D) Stability test of IR/Lap/CUDC NPs under physiological conditions for 48 h. E) Size distribution changes of IR/Lap/CUDC NPs after H 2 O 2 incubation. F) Fluorescent spectra of IR/Lap/CUDC NPs with or without H 2 O 2 incubation. G) UV–vis absorption spectra of IR/Lap/CUDC NPs with or without H 2 O 2 incubation. H) Cell viability of 4T1 cells treated with gradient concentrations of free β ‐lap and CUDC101. I) Synergy score of free β ‐lap and CUDC101 in 4T1 cells at gradient concentrations calculated by the Highest Single Agent (HSA) model in SynergyFinder. "NPs" shown in (E), (F), and (G) refers to IR/Lap/CUDC NPs.
Article Snippet: β ‐lapachone ( β ‐lap), crystal violet, and DNase I were obtained from Macklin (Shanghai, China).
Techniques: Transmission Assay, Electron Microscopy, Zeta Potential Analyzer, Incubation